Anxiety · anxiolyticSleep · circadianRussia-registered (Selank)
Calm & Sleep
Stack: Selank + DSIP · the calming, sleep-support side of the neuro category
"The down-regulation counterpart to the focus and neuroprotection stacks. Selank takes the edge off anxiety without sedation or dependence; DSIP is a much more speculative sleep-onset add. Honest framing: Selank has the better data, DSIP is the most experimental piece here, and neither is a UK-licensed medicine."
GoalAnxiety reduction / sleep quality
Compounds2 · Selank + DSIP
Human evidenceLimited–moderate — Russian clinical (Selank); DSIP mixed
StatusUK: unlicensed research chemicals — not controlled, legal to possess, but not approved medicines. Russia: Selank registered for anxiety; DSIP studied as Deltaran
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Registered use (Russia)
Selank
A registered anxiolytic medicine in Russia (developed at the Institute of Molecular Genetics), in clinical use for generalised anxiety since the 1990s.
DSIP
Studied in the former USSR as "Deltaran"; never a broadly registered pharmaceutical, and never licensed in the UK, US or EU.
Evidence it adds
Real-world Russian clinical exposure for Selank — far less for DSIP.
Basis: Russian pharmacology registration (Selank)
Research / trial evidence
Selank
Russian RCTs describe anxiolytic and mild nootropic effects without the sedation or dependence of benzodiazepines — modest sample sizes, limited Western replication.
DSIP
Older, inconsistent human data. DSIP does not reliably act as a hypnotic in controlled trials; its mechanism remains unresolved.
Evidence it adds
Moderate for Selank; weak and speculative for DSIP.
Basis: Russian clinical literature · limited Western RCTs
Grey-market / unsupervised use
Where / who
Both are sold as research peptides — Selank usually intranasal, DSIP reconstituted for subcutaneous use before sleep.
What changes
Product identity, purity and dose are unverified; the Russian safety record belongs to the registered product, not a grey-market vial.
Evidence it adds
None — this layer is about how unsupervised use diverges from the studied product.
Basis: real-world sourcing — not a trial tier
Regulatory — read carefully
MHRA (UK)
Neither is a licensed medicine and neither is a controlled drug — unlicensed research chemicals. "Legal to possess" is not "approved or safe".
Elsewhere
Selank is registered in Russia; DSIP has no broad approval anywhere. Not FDA/EMA-approved.
What it means
Low apparent toxicity, but thin evidence — especially for DSIP.
Basis: MHRA: unlicensed, not scheduled
Why this is the foundation
The neuro section already covers the up-regulation side — Semax-based focus stacks and neuroprotection. This pairing is the opposite direction: calming and sleep. Selank is the anchor — a Russia-registered anxiolytic with a real, if modest, clinical record, used for anxiety without the sedation or dependence of benzodiazepines. DSIP is the speculative add: a sleep-onset peptide whose human evidence is old and inconsistent. The honest framing: run Selank for the anxiety data it actually has, and treat DSIP as experimental — not a proven sleep aid.
Members only · the actionable depth
See exactly how it's run
Doses, titration structure and what to monitor are part of membership. The provenance, evidence and status above are always free.
Get the tracker · £4.99/mo →
£4.99/mo · cancel anytime
Cycle shape — how it's typically structured, not a schedule to follow
Selank
intranasal, daily / as needed
DSIP
pre-sleep, nights needed
Selank is typically used intranasally through the day or before stressful events; DSIP before sleep on an as-needed basis. These mirror community and Russian-clinical patterns, not a prescription to follow.
What's worth monitoring
Both peptides have a low reported toxicity profile, and Selank in particular is noted for the absence of sedation, tolerance or dependence seen with conventional anxiolytics. The real caveats are evidential and practical: DSIP is the least proven piece and may simply not do much; and grey-market product identity and purity are unverified. Baseline sensibility and a clinician conversation are the floor. General information, not medical advice.
Pep IQ